PASG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PASG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Passage Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, Passage Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Passage Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Passage Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Passage Bio (NAS:PASG) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Passage Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Kathleen Borthwick | officer: SVP, Interim CFO | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Simona King | officer: Chief Financial Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Dolan Sondhi | director | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Alexandros Fotopoulos | officer: Chief Technical Officer | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Sandip Kapadia | director | 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011 |
William Chou | director, officer: Chief Executive Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Monika Maria Toernsen | officer: Chief Commercial Officer | ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Michael E. Kamarck | director | C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406 |
Mark S Forman | officer: Chief Medical Officer | C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
Bruce A Goldsmith | director, officer: CEO and President | C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103 |
Orbimed Capital Gp Vii Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Brian Burkavage | officer: Controller | C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103 |
Derrell Porter | director | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
From GuruFocus
By sperokesalga sperokesalga • 04-17-2023
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 02-24-2023
By sperokesalga sperokesalga • 04-21-2023
By Marketwired • 08-01-2023
By PurpleRose PurpleRose • 08-11-2022
By sperokesalga sperokesalga • 05-11-2023
By Value_Insider Value_Insider • 11-08-2022
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 10-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.